UAE Begins Mapping Air Corridors for Air Taxis and Cargo Drones to Transform Urban Transportation
13.2.2025 18:12:00 CET | Business Wire | Press release
Initial advanced air mobility (AAM) regulations under development for the UAE GCAA and ATRC entities – TII and ASPIRE collaborate on technical expertise and airspace management
The UAE has taken a bold step towards redefining urban transportation with the commencement of air corridor mapping and regulatory framework development for piloted and autonomous air taxis and cargo drones. This transformative initiative marks a major leap forward in the nation’s mission to lead the future of mobility. Through a strategic partnership between the General Civil Aviation Authority (GCAA) and the Advanced Technology Research Council (ATRC) entities—Technology Innovation Institute (TII) and ASPIRE—the UAE is on track to reshape the way people and goods move through urban spaces.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213996930/en/
UAE Begins Mapping Air Corridors for Air Taxis and Cargo Drones to Transform Urban Transportation (Photo: AETOSWire)
With aerial corridors and regulations set to be defined within the next 20 months, this pioneering effort demonstrates the UAE’s unwavering commitment to deploying safe, advanced, sustainable transportation solutions that will not only ease congestion but also set a global benchmark for future urban mobility systems. These routes will connect key international airports and iconic places in the UAE, extending further to ensure seamless integration of piloted and autonomous air taxis and cargo drones across the nation’s urban landscapes.
His Excellency Saif Mohammed Al Suwaidi, Director General of the GCAA said: “Air corridor mapping for piloted and autonomous air taxis and drones is a crucial milestone that will enable the seamless implementation of Advanced Air Mobility into the UAE’s infrastructure. This initiative ensures the safe and efficient adoption of air mobility, delivering transformative solutions to urban transport and paving the way for a smarter, more connected future.”
The UAE’s forward-thinking approach to urban transportation will be supported by TII’s expertise in airspace management, ensuring the safe integration of piloted and autonomous air taxis and cargo drones into urban environments. These new air corridors will offer innovative solutions for passenger and cargo transport, relieving pressure on traditional road networks and improving connectivity.
Dr. Najwa Aaraj, CEO of TII, said: “This transformative collaboration with GCAA is reshaping the future of urban transportation. By advancing airspace management and integrating piloted and autonomous air taxis and cargo drones, we are not only enhancing urban connectivity but also driving sustainable and accessible mobility solutions that will benefit future generations.”
Stephane Timpano from ASPIRE said: “Addressing real-time urban mobility challenges through innovative solutions like air taxis and drones is a major step forward. This initiative directly supports sustainable economic growth by creating a flexible and diverse transport system that eases pressure on urban infrastructure and fosters smarter, more resilient cities.”
The agreement was announced during World Governments Summit 2025.
Advanced Air Mobility (AAM) refers to the use of automated aircraft in urban and suburban settings to deliver innovative transport solutions for people and goods. With TII at the helm of developing the technical aspects of AAM and ASPIRE focusing on creating a network of stakeholders, including regulators, industry leaders, and researchers, this collaboration aims to establish a comprehensive regulatory framework that ensures safety and operational efficiency.
Prof. Enrico Natalizio, Chief Researcher of the Autonomous Robotics Research Center at TII, commented: “At TII, we’re developing advanced AI-powered control, vision and communication algorithms for autonomous systems that enable real-time decision-making for air taxis and drones. Having mastered this technology, we are able to propose methodologies for AAM corridors design to optimize routes, ensure collision avoidance, and integrate seamlessly with urban airspace, marking a key step toward efficient and safe autonomous air mobility in complex urban environments.”
Together with GCAA, these entities will define the airspace regulations and develop airspace management systems, making the UAE a global benchmark for advanced urban mobility.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213996930/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom